Patrick Pun, MD MHS FASN (@virtualpun) 's Twitter Profile
Patrick Pun, MD MHS FASN

@virtualpun

Nephrologist and Clinical Researcher at Duke University School of Medicine/Durham VA Medical Center

ID: 2359692024

linkhttp://virtualpun.com calendar_today24-02-2014 15:50:42

23 Tweet

399 Takipçi

16 Takip Edilen

Patrick Pun, MD MHS FASN (@virtualpun) 's Twitter Profile Photo

New research led by former Duke University School of Medicine student Sam Hofacker / MassGeneral Medicine intern Important racial disparities in CPR initiation observed in US dialysis clinics "Of all forms of inequality, injustice in health is most shocking and inhuman" Dr MLK Jr resuscitationjournal.com/article/S0300-…

New research led by former <a href="/DukeMedSchool/">Duke University School of Medicine</a> student <a href="/shofacker/">Sam Hofacker</a> / <a href="/MGHMedicine/">MassGeneral Medicine</a> intern

Important racial disparities in CPR initiation observed in US dialysis clinics

"Of all forms of inequality, injustice in health is most shocking and inhuman" Dr MLK Jr
 
resuscitationjournal.com/article/S0300-…
Sam Hofacker (@shofacker) 's Twitter Profile Photo

Hi #Medtwitter, #Nephtwitter! I’ve wanted to put together a tweetorial for a while, and now that my first manuscript is published, here are a few things I’ve learned about cardiac arrest in patients on dialysis, our resuscitative response, and #healthequity. Thread:

Duke Kidney (@dukekidney) 's Twitter Profile Photo

.Patrick Pun, MD MHS FASN Duke Clinical Research Institute and colleagues in @CJASN Trends in Use and In-Hospital Outcomes of Subcutaneous Implantable Cardioverter Defibrillators in Patients Undergoing Long-Term Dialysis cjasn.asnjournals.org/content/early/…

.<a href="/virtualpun/">Patrick Pun, MD MHS FASN</a> <a href="/DCRINews/">Duke Clinical Research Institute</a>  and colleagues in @CJASN 

Trends in Use and In-Hospital Outcomes of Subcutaneous Implantable Cardioverter Defibrillators in Patients Undergoing Long-Term Dialysis

cjasn.asnjournals.org/content/early/…
Susan Quaggin (@susanquaggin) 's Twitter Profile Photo

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes | NEJM. When it 🌧 sometimes it pours in the most positive way!! Another #win for the kidney community! can’t wait to check out the late breakers ⁦American Society of Nephrology⁩ #KidneyWk nejm.org/doi/full/10.10…

Duke Kidney (@dukekidney) 's Twitter Profile Photo

.Sam Hofacker Patrick Pun, MD MHS FASN and colleagues in Nephrology Nursing Journal Barriers and Facilitators to Performing Cardiopulmonary Resuscitation During Treatment in Outpatient Hemodialysis Clinics: A Qualitative Study pubmed.ncbi.nlm.nih.gov/33107712/

Patrick Pun, MD MHS FASN (@virtualpun) 's Twitter Profile Photo

concept of "isothermic" dialysis is intriguing-- are we harming some patients by setting dialysate temp to 37? cjasn.asnjournals.org/content/early/…

Patrick Pun, MD MHS FASN (@virtualpun) 's Twitter Profile Photo

Another great question is what to do about subclinical Afib, detected during HD in 20% of HD pts with ICDs ncbi.nlm.nih.gov/pubmed/24670418 #askasn

Patrick Pun, MD MHS FASN (@virtualpun) 's Twitter Profile Photo

The 2017 American College of Radiology guidelines on contrast say that the risk of NSF with class II gadolinium agents is "sufficiently low or possibly non-existent" and recommend that no informed consent is needed for CKD pts. Does absence of evidence= absence of risk? #AskASN

Patrick Pun, MD MHS FASN (@virtualpun) 's Twitter Profile Photo

But If we have stopped using gadolinium in ckd due to risk of nsf, how can we have any data that risk in ckd is “sufficiently low or nonexistent”? Do we need more evidence specifically in ckd pts before we subject our patients to gadolinium without informed consent?